BLASUBCUTANEOUSSOLUTION
Approved
Jul 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ADLYXIN (lixisenatide) by Sanofi is 100/33 soliqua 100/33 is a combination of insulin glargine, a basal insulin analog, and lixisenatide, a glp-1 receptor agonist. Approved for type 2 diabetes mellitus. First approved in 2016.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADLYXIN (lixisenatide) is a GLP-1 receptor agonist approved in 2016 for type 2 diabetes mellitus. It is also marketed as SOLIQUA 100/33, a fixed-dose combination with insulin glargine that regulates glucose metabolism through dual mechanisms: insulin glargine stimulates peripheral glucose uptake and inhibits hepatic production, while lixisenatide enhances glucose-dependent insulin release and slows gastric emptying. The subcutaneous solution formulation addresses patients requiring intensified glycemic control.
Peak
ADLYXIN operates in a mature diabetes combination market at peak lifecycle stage; commercial teams focus on maintaining share against stronger GLP-1 monotherapy and SGLT2i competitors.
Mechanism of Action
100/33 SOLIQUA 100/33 is a combination of insulin glargine, a basal insulin analog, and lixisenatide, a GLP-1 receptor agonist. Insulin glargine The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by…
Indications (1)
Clinical Trials (20)
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
Started Mar 2019
265 enrolled
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Started Feb 2019
426 enrolled
Type 2 Diabetes Mellitus
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Started Feb 2019
878 enrolled
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Started Jun 2018
247 enrolled
Type 2 Diabetes Mellitus
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
Started Jun 2018
156 enrolled
Parkinson Disease
Worked on ADLYXIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.